Chicago, Illinois – Liver disease specialists at the University of Chicago Medicine will soon begin prescribing a first-of-its-kind drug for treating advanced metabolic dysfunction-associated steatotic liver disease (MASLD) — formerly known as nonalcoholic fatty liver disease (NAFLD). Resmetirom (to be sold under the brand name Rezdiffra), received FDA approval on March 14, 2024....
treatment News
Cincinnati, Ohio – The University of Cincinnati Cancer Center is the first site in the Midwest enrolling patients in a new Phase 2 clinical trial testing a vaccine to treat pancreatic cancer. According to the National Cancer Institute, more than 66,000 Americans will be diagnosed with pancreatic cancer in 2024....
San Diego, Ca – University of Cincinnati Cancer Center researchers will present abstracts at the American Society of Hematology (ASH) Annual Meeting, held Dec. 9-12 in San Diego, California. Trial finds new drug shows promise to treat Chronic Lymphocytic Leukemia (CLL) Phase 2 clinical trial results suggest a new drug...
Cincinnati, OH – While the overall cancer death rate has been steadily declining in the U.S. since the 1990s, death rates due to pancreatic cancer are increasing. This is especially true in pancreatic cancer that has metastasized, or spread to a different part of the body. The National Cancer Institute...
Cologne, Germany – In the treatment of aggressive lymphomas and blood cancer (leukaemia), so-called chimeric antigen receptor T cells (CAR T cells) are increasingly being used. For this therapy, immune cells are taken from patients and programmed by means of genetic engineering to detect proteins on the malignant tumour cells....
Geneva, Switzerland – Cystic fibrosis is a genetic disease that causes serious and sometimes fatal respiratory and digestive disorders. A new treatment, available since 2020, improves lung function and quality of life. However, it does not always eradicate the bacteria responsible for respiratory infections. By studying 3D models of human...
Leeds, UK – Personalised treatment for the most common form of adult leukaemia helps patients survive for longer and stay in remission, a phase III trial has found. The trial, by the University of Leeds, has been identified as groundbreaking research by the New England Journal of Medicine and the...
Baltimore MD – A drug approved to treat pulmonary arterial hypertension may be effective at managing hypertension and end-organ damage in patients with sickle cell disease, according to a new study published in Lancet Haematology. An early phase randomized clinical trial involving 130 patients with sickle cell disease found that...
MIAMI, FLORIDA – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations has identified a next-generation BTK degrader that could help overcome treatment resistance in chronic lymphocytic leukemia (CLL) and related blood cancers. Their findings, published in the journal Science,...
Ann Arbor, Mich. – Early treatment of pediatric Crohn’s disease with anti-tumor necrosis factor medications can substantially reduce the risk of perianal fistulas, a particularly debilitating complication of Crohn’s disease. Michigan Medicine researchers confirmed this finding using prospective data. The resulting paper, “Early tumour necrosis factor antagonist treatment prevents perianal...